6 ways to hedge currency risk in foreign equity 2021/05/27 04:19:32 Economic Times India
1,000% return in just 10 years. No, we are not talking about a penny stock or worse, not a Ponzi scheme. This is the kind of returns earned by those investors who invested in the stocks of American mega corporates like Apple, Microsoft, Tesla, and Amazon 10 years ago. That is right, if you had invested Rs 1 lakh in any of these multi-baggers back in 2011, your investment would be worth more than Rs 10 crore today. And now, despite being a pandemic year, the US stock markets closed at record highs in 2020. This has piqued the interest of many Indian investors who are either taking the direct equity route or are using mutual funds to invest in not just the US market but other global markets as well. Many Indian fund houses have even launched mutual fund schemes to cater to this demand. While many of these stocks have returned handsome gains and global equities are a good way to diversify, but before jumping on the bandwagon and putting in the money to invest, one should also be mindful of the risks.
Michael Parini Sells 400 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock 2021/02/07 10:24:47 Watchlist News
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Michael Parini sold 400 shares of the firm’s stock in a transaction on Wednesday, February 3rd. The shares were sold at an average price of $216.56, for a total value of $86,624.00. Following the transaction, the executive vice president now owns 35,276 shares in the company, valued at approximately $7,639,370.56. […]
3 Reasons It's Not Too Late to Buy Vertex Pharmaceuticals 2021/02/05 12:55:00 The Motley Fool
Here's why you should still pick up shares of this high-flying biotech.
Uber, UPS rise; Vertex Pharmaceuticals, BP fall 2021/02/02 21:22:59 ABC News
Stocks that traded heavily or had substantial price changes Tuesday: Uber, UPS rise; Vertex Pharmaceuticals, BP fall
Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS 2021/02/02 16:52:41 Transcript Daily
Vertex Pharmaceuticals (NASDAQ:VRTX) issued its quarterly earnings results on Sunday. The pharmaceutical company reported $2.51 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.59 by ($0.08), MarketWatch Earnings reports. Vertex Pharmaceuticals had a net margin of 38.51% and a return on equity of 28.55%. During the same period last […]
STAT+: Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call 2021/02/02 13:29:49 STAT News
Who (or what) is Vertex Pharmaceuticals going to buy? The question — asked many different ways by analysts — dominated the company’s year-end earnings conference call.
RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals 2020/12/10 01:57:37 Investing.com
RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals
Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years 2020/11/27 08:00:00 Business Wire
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for SYMKEVI® (tezacaftor/ivacaftor) with KALYDECO® (ivacaftor), to include the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or one copy of the F508del mutation and one copy of one of 14 mutations
Odds Of Vertex's Pipeline Success Aren't Dismal As Some Fear, Bernstein Says 2020/11/20 15:45:07 Benzinga
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) shares have come under selling pressure recently, given investor concern regarding diversity in the pipeline for this cystic fibrosis-focused biopharma. The Vertex Analyst: Bernstein analyst Analyst Vincent Chen initiated coverage of Vertex with an Outperform rating and $275 price target. The Vertex Thesis: Vertex's pipeline is underappreciated and offers substantial upside optionality, Chen said in a note. The cystic fibrosis franchise could reach sales of about $10 billion by 2025, with patent exclusivity into the late 2030s and strong potential for lifecycle … Full story available on Benzinga.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Earns Outperform Rating from Analysts at Sanford C. Bernstein 2020/11/20 13:32:45 Transcript Daily
Sanford C. Bernstein started coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report issued on Friday, The Fly reports. The brokerage set an “outperform” rating and a $275.00 price target on the pharmaceutical company’s stock. Sanford C. Bernstein’s target price suggests a potential upside of 29.74% from the stock’s current price. A number […]
Cystic fibrosis drug Trikafta could change lives - if Health Canada approves it 2020/11/18 09:00:00 CBC News
After a year of hesitation in the face of pending cost control guidelines, Vertex Pharmaceuticals has submitted Trikafta to Health Canada for approval - now the hard work begins, writes Jeremie Saunders.